A Look at Artivion’s (AORT) Valuation Following Strong Q3 Results and Raised Full-Year Guidance

Simply Wall St.11-25

Artivion (AORT) just announced third-quarter results that outperformed expectations, and the company raised its full-year revenue and EBITDA guidance. Analysts responded by maintaining upbeat outlooks...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2586472132?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","is_english":true,"pubTime":"2025-11-25 22:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586472132","market":"us","top_or_hot":-1,"title":"A Look at Artivion’s (AORT) Valuation Following Strong Q3 Results and Raised Full-Year Guidance","media":"Simply Wall St.","content":"<div>\n<p>Artivion (AORT) just announced third-quarter results that outperformed expectations, and the company raised its full-year revenue and EBITDA guidance. Analysts responded by maintaining upbeat outlooks...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-aort/artivion/news/a-look-at-artivions-aort-valuation-following-strong-q3-resul\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look at Artivion’s (AORT) Valuation Following Strong Q3 Results and Raised Full-Year Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look at Artivion’s (AORT) Valuation Following Strong Q3 Results and Raised Full-Year Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-25 22:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-aort/artivion/news/a-look-at-artivions-aort-valuation-following-strong-q3-resul><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Artivion (AORT) just announced third-quarter results that outperformed expectations, and the company raised its full-year revenue and EBITDA guidance. Analysts responded by maintaining upbeat outlooks...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-aort/artivion/news/a-look-at-artivions-aort-valuation-following-strong-q3-resul\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0031619046.USD","symbol_name":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-aort/artivion/news/a-look-at-artivions-aort-valuation-following-strong-q3-resul","article_id":"2586472132","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-aort/artivion/news/a-look-at-artivions-aort-valuation-following-strong-q3-resul","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2586472132","pubTimestamp":1764081025,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Artivion (AORT) just announced third-quarter results that outperformed expectations, and the company raised its full-year revenue and EBITDA guidance. Analysts responded by maintaining upbeat outlooks for the stock and citing strong operational momentum.\nSee our latest analysis for Artivion.\nOn the back of upbeat third-quarter results and growing operational confidence, Artivion’s share price has rallied, posting a striking 63.1% return so far this year. The company’s strong execution has...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0031619046.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC","AORT":"Artivion","IE00B7SZL793.SGD":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","IE00B19Z4B17.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC","BK4082":"医疗保健设备","IE00B66KJ199.SGD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY  \" A\" (SGD) ACC"},"translate_title":"第三季度业绩强劲并上调全年指引后，看看Artivion(AORT)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AORT":1.5},"content_text":"Artivion (AORT) just announced third-quarter results that outperformed expectations, and the company raised its full-year revenue and EBITDA guidance. Analysts responded by maintaining upbeat outlooks for the stock and citing strong operational momentum. See our latest analysis for Artivion. On the back of upbeat third-quarter results and growing operational confidence, Artivion’s share price has rallied, posting a striking 63.1% return so far this year. The company’s strong execution has fueled renewed market enthusiasm, and recent leadership share sales have done little to dampen the positive momentum. With a three-year total shareholder return of 261.6%, investors have seen both short-term gains and robust long-term growth. If Artivion’s breakout run has you scanning for other compelling opportunities, now is the perfect time to explore See the full list for free. But with the stock achieving such stellar gains and analysts already raising their targets, investors are left wondering: is Artivion still trading at an attractive value, or has the market already priced in the company’s future growth prospects? AdvertisementMost Popular Narrative: 11.4% Undervalued With the most followed narrative assigning a fair value of $51.71 compared to the last close price of $45.81, Artivion is seen as having room to climb. This positioning sets up a compelling debate about just how bullish the current outlook has become.  Ongoing U.S. launch of AMDS, with positive physician feedback, rapid clinical adoption post-training, and a significant $150 million annual market opportunity, indicates accelerating market penetration. This should materially contribute to both top-line revenue growth and high-margin product mix, improving EBITDA margins long-term.  Read the complete narrative. Curious how bold future earnings, expanding profit margins, and new product success combine to produce this double-digit upside? The growth assumptions and financial leaps behind the fair value might surprise you. Only the full deep dive reveals the narrative’s most ambitious projections. Are you ready to see what’s fueling the optimism? Result: Fair Value of $51.71 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, persistent regulatory hurdles or increased competition in heart valve devices could quickly challenge Artivion’s projected growth and valuation optimism. Find out about the key risks to this Artivion narrative. Another View: Price Ratios Tell a Different Story While narrative-based models suggest double-digit upside, Artivion is trading at a price-to-sales ratio of 5.1x, which is notably higher than both its industry average of 3x and its peer group at 3.8x. Compared to a fair ratio estimate of 2.7x, this premium signals that investors are already paying up for future growth. Does the market see opportunity others miss, or is there risk of sentiment outpacing results? See what the numbers say about this price — find out in our valuation breakdown. NYSE:AORT PS Ratio as at Nov 2025 Build Your Own Artivion Narrative If you want to dig into the numbers yourself or think another angle is worth considering, shaping your own Artivion narrative takes just a few minutes, so why not Do it your way A great starting point for your Artivion research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision. Looking for More Investment Ideas? Don’t let your search end here. Your next winning stock could be one smart move away. Expand your horizons and set yourself up for success with these handpicked opportunities:  Unlock the potential of high-yield portfolios by taking a closer look at these 14 dividend stocks with yields > 3% offering steady income beyond the usual blue chips. Tap into transformative tech trends shaping tomorrow when you browse these 26 AI penny stocks packed with AI-driven innovation and disruptive business models. Boost your value strategy with these 922 undervalued stocks based on cash flows, where overlooked gems stand ready for new attention from active investors like you.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2586472132","isCrawlerRequest":true}